Free Trial
NASDAQ:CMRX

Chimerix Q4 2024 Earnings Report

Chimerix EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Chimerix Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.31 million
Beat/Miss
Missed by -$254.00 thousand
YoY Revenue Growth
N/A

Chimerix Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
6:00AM ET

Chimerix Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Chimerix reports Q4 EPS (25c), consensus (28c)
See More Chimerix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chimerix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chimerix and other key companies, straight to your email.

About Chimerix

Chimerix (NASDAQ:CMRX), a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

View Chimerix Profile

More Earnings Resources from MarketBeat